Roche Holding Company Profile (NASDAQ:RHHBY)

About Roche Holding (NASDAQ:RHHBY)

Roche Holding logoRoche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RHHBY
  • CUSIP: N/A
  • Web:
Average Prices:
  • 50 Day Moving Avg: $32.96
  • 200 Day Moving Avg: $30.58
  • 52 Week Range: $25.25 - $36.82
  • Trailing P/E Ratio: 24.43
  • Foreward P/E Ratio: 16.86
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $52.98 billion
  • Price / Sales: N/A
  • Book Value: $3.53 per share
  • Price / Book: 9.69
  • Dividend Yield: 3.0%
  • EBIDTA: $20.76 billion
  • Average Volume: 1.03 million shs.

Frequently Asked Questions for Roche Holding (NASDAQ:RHHBY)

What is Roche Holding's stock symbol?

Roche Holding trades on the NASDAQ under the ticker symbol "RHHBY."

Where is Roche Holding's stock going? Where will Roche Holding's stock price be in 2017?

7 brokers have issued 12 month price objectives for Roche Holding's shares. Their predictions range from $33.37 to $33.37. On average, they expect Roche Holding's share price to reach $33.37 in the next year. View Analyst Ratings for Roche Holding.

Who are some of Roche Holding's key competitors?

Who owns Roche Holding stock?

Roche Holding's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.00%), Parametric Portfolio Associates LLC (0.00%), Schafer Cullen Capital Management Inc. (0.00%), Bristol John W & Co. Inc. NY (0.00%), Riverbridge Partners LLC (0.00%) and Moody Lynn & Lieberson LLC (0.00%). View Institutional Ownership Trends for Roche Holding.

Who sold Roche Holding stock? Who is selling Roche Holding stock?

Roche Holding's stock was sold by a variety of institutional investors in the last quarter, including Bristol John W & Co. Inc. NY, Commerce Bank, Scout Investments Inc., Blair William & Co. IL, Cape Cod Five Cents Savings Bank, Tower Bridge Advisors, Wendell David Associates Inc. and Thomas White International Ltd.. View Insider Buying and Selling for Roche Holding.

Who bought Roche Holding stock? Who is buying Roche Holding stock?

Roche Holding's stock was acquired by a variety of institutional investors in the last quarter, including Parametric Portfolio Associates LLC, Moody Lynn & Lieberson LLC, Schafer Cullen Capital Management Inc., Fisher Asset Management LLC, Oxbow Advisors LLC, Kempner Capital Management Inc., Riverbridge Partners LLC and Sit Investment Associates Inc.. View Insider Buying and Selling for Roche Holding.

How do I buy Roche Holding stock?

Shares of Roche Holding can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Roche Holding stock cost?

One share of Roche Holding stock can currently be purchased for approximately $34.22.

Analyst Ratings

Consensus Ratings for Roche Holding (NASDAQ:RHHBY) (?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $33.37 (2.48% downside)

Analysts' Ratings History for Roche Holding (NASDAQ:RHHBY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/7/2017HSBC Holdings plcDowngradeHold -> ReduceLowView Rating Details
4/5/2017Cowen and CompanyUpgradeMarket Perform -> Outperform$25.25 -> $33.37LowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageHold -> HoldLowView Rating Details
3/7/2017Barclays PLCInitiated CoverageOverweightN/AView Rating Details
2/19/2017Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
12/7/2016Sanford C. BernsteinReiterated RatingOverweightN/AView Rating Details
8/3/2016Citigroup IncReiterated RatingBuyN/AView Rating Details
(Data available from 5/25/2015 forward)


Earnings History for Roche Holding (NASDAQ:RHHBY)
No earnings announcements for this company have been tracked by


Earnings Estimates for Roche Holding (NASDAQ:RHHBY)
Current Year EPS Consensus Estimate: $1.91 EPS
Next Year EPS Consensus Estimate: $2.03 EPS


Dividend History for Roche Holding (NASDAQ:RHHBY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Roche Holding (NASDAQ:RHHBY)
No insider trades for this company have been tracked by


Headline Trends for Roche Holding (NASDAQ:RHHBY)
Latest Headlines for Roche Holding (NASDAQ:RHHBY)
DateHeadline logoWide-Moat Roche Is Undervalued - May 24 at 9:47 AM logo3 Things In Biotech You Should Learn Today: May 11, 2017 - May 11 at 7:59 PM logoGenentech to Present New Data on Personalized Medicines and Cancer Immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting - May 11 at 7:59 PM logoRoche Throws a New Wrinkle Into the IO Market - May 10 at 7:46 PM logoGenentech Provides Update on Phase III Study of TECENTRIQ (Atezolizumab) in People with Previously Treated Advanced Bladder Cancer - May 10 at 11:14 AM logoCancer Immunotherapy Fallout From Roche's Bladder Cancer Failure - May 10 at 11:14 AM logoRoche Holding Ltd. (RHHBY) Lowered to "Hold" at Zacks Investment Research - May 9 at 12:14 PM logoThe Zacks Analyst Blog Highlights: Arcelor Mittal, Roche Holding AG and Cummins - May 9 at 10:47 AM logoRoche receives FDA approval for complementary PD-L1 (SP263) biomarker test in urothelial carcinoma - May 2 at 5:21 PM logoExelixis (EXEL) Posts Earnings in Q1, Cabometyx in Focus - May 2 at 5:21 PM logoRoche Holding Ltd. (RHHBY) Receives Average Rating of "Buy" from Analysts - May 2 at 2:20 PM logoMorningstar: This Large Biotech Could Be The World's Best Stock - May 1 at 6:50 PM logoFDA clears Roche high-volume immunoassay lab testing solution to support critical medical treatment decisions - May 1 at 10:18 AM logoRoche Q1 2017: Strong Signals For Investors - Seeking Alpha - April 28 at 3:42 PM logo[$$] Roche Revenue Up 4% - April 27 at 7:59 PM logoRoche Tops the Swiss Market After First Quarter Sales Beat Expectations - April 27 at 10:57 AM logoNew Data at AAN Reinforce Clinical Benefit of Genentech’s OCREVUS (Ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis - April 26 at 5:43 PM logoIndia's antitrust watchdog orders probe into Roche cancer drug - April 26 at 5:43 PM logoRoche Holding Ltd. (RHHBY) Downgraded by Zacks Investment Research to Hold - April 20 at 12:58 PM logoGenentech to Present New Data at AAN Reinforcing Efficacy and Safety of Newly FDA Approved OCREVUS (Ocrelizumab) in Two Types of Multiple Sclerosis - April 19 at 9:35 AM logoRoche's (RHHBY) Cancer Drug Gets FDA Nod for Label Expansion - April 18 at 6:50 PM logoRoche's Hemophilia A Drug Positive in Second Phase III Study - April 18 at 9:30 AM logoFDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age Adults in the United States - April 17 at 6:34 PM logoRoche's Genentech says its drug for diabetes complication has been approved by FDA - April 17 at 6:34 PM logoFDA Grants Genentech’s TECENTRIQ (Atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanced Bladder Cancer - April 17 at 6:34 PM logoGenentech Announces Positive Interim Results for Emicizumab in Phase III Study of Children with Hemophilia A - April 17 at 9:17 AM logoRoche Launches Antibody Test to Diagnose Prostate Cancer - April 13 at 7:22 PM logoRoche launches new global Certified Provider Program for Target Enrichment in Genomic Sequencing - April 11 at 7:19 PM logo4 Reasons Why Roche Will Have the Best Growth in Big Pharma... and 1 Reason Why It Won't - April 11 at 7:19 PM logoPhase III Study Shows Genentech’s Alecensa® Was Superior to Crizotinib in a Specific Type of Lung Cancer - April 10 at 9:26 AM logoHSBC Holdings plc Lowers Roche Holding Ltd. (RHHBY) to Reduce - April 7 at 8:22 PM logoRoche Holding Ltd. (RHHBY) Upgraded to Outperform by Cowen and Company - April 6 at 12:24 AM logoRoche Holding Ltd. (RHHBY) Given Average Rating of "Buy" by Analysts - April 5 at 3:42 PM logoRoche's Alecensa Succeeds in Lung Cancer Phase 3 - April 3 at 7:05 PM logoRoche Holding Ltd. (RHHBY) Upgraded by Zacks Investment Research to "Buy" - April 3 at 12:55 PM logoHealthcare: Stock-Picking Increasingly Important as Valuations Rise - March 31 at 8:17 AM logoRoche's MS Drug Ocrevus Secures FDA Nod - March 29 at 8:47 PM logoFDA Advisory Committee Unanimously Recommends Approval of Genentech’s Subcutaneous Rituximab for Certain Blood Cancers - March 29 at 8:47 PM logoFDA Approves Genentech’s OCREVUS™ (Ocrelizumab) for Relapsing and Primary Progressive Forms of Multiple Sclerosis - March 29 at 12:24 AM logoRoche Holding Ltd. (RHHBY) Upgraded to Buy by Zacks Investment Research - March 28 at 12:33 PM logoProtalix Biotherapeutics: High Expectations For Upcoming Phase 2 Cystic Fibrosis Readout - March 27 at 9:26 AM logoShould Value Investors Pick Roche Holding (RHHBY)? - Yahoo Finance - March 25 at 12:22 AM logoFDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris - March 24 at 1:03 AM logoYestar Healthcare Holdings Company Limited -- Moody's: Yestar's 2016 results are in line with expectations - March 17 at 1:21 AM logoRoche launches the cobas® EGFR Mutation Test v2 for use with either plasma or tumor tissue samples - March 14 at 9:52 AM logoRoche Diagnostics recognizes Poplar Healthcare as Roche Molecular Center of Excellence - March 13 at 9:32 AM logoEuropean Health Care Stocks Wobble After Trump Tweet on Drug Prices - March 7 at 9:27 AM logoRoche Shares Boosted by Cancer Drug Trial Success - March 3 at 12:40 AM logoRoche Shows More Fundamental And Technical Strength - March 2 at 7:39 PM logo3:42 am Roche Hldg unit Genentech reports results from the Phase III APHINITY study for Perjeta met its primary endpoint - March 2 at 7:39 PM



Roche Holding (RHHBY) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by Staff